Dimension Therapeutics Inc. (DMTX) Cut to “Sell” at Zacks Investment Research
Dimension Therapeutics Inc. (NASDAQ:DMTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.
According to Zacks, “Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company’s pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts. “
A number of other equities research analysts have also recently weighed in on the company. Jefferies Group set a $12.00 price target on Dimension Therapeutics and gave the stock a “buy” rating in a report on Monday, September 12th. Cantor Fitzgerald restated a “buy” rating on shares of Dimension Therapeutics in a report on Wednesday, June 22nd. Canaccord Genuity set a $20.00 price target on Dimension Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 11th. Finally, Chardan Capital set a $10.00 price target on Dimension Therapeutics and gave the stock a “hold” rating in a report on Sunday, August 21st. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. Dimension Therapeutics has an average rating of “Buy” and a consensus price target of $17.19.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/dimension-therapeutics-inc-dmtx-cut-to-sell-at-zacks-investment-research-2.html
Dimension Therapeutics (NASDAQ:DMTX) traded up 4.56% during midday trading on Monday, reaching $7.34. The company’s stock had a trading volume of 35,626 shares. The firm’s 50-day moving average price is $7.69 and its 200-day moving average price is $7.47. The stock’s market capitalization is $183.71 million. Dimension Therapeutics has a 52 week low of $5.39 and a 52 week high of $15.55.
Dimension Therapeutics (NASDAQ:DMTX) last released its earnings results on Thursday, August 11th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. Dimension Therapeutics had a negative return on equity of 66.58% and a negative net margin of 459.47%. On average, analysts anticipate that Dimension Therapeutics will post ($1.91) earnings per share for the current year.
Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its stake in Dimension Therapeutics by 50.5% in the first quarter. JPMorgan Chase & Co. now owns 239,000 shares of the company’s stock worth $1,871,000 after buying an additional 80,200 shares during the last quarter. Geode Capital Management LLC acquired a new position in shares of Dimension Therapeutics during the first quarter worth $462,000. State Street Corp raised its position in shares of Dimension Therapeutics by 46.2% in the first quarter. State Street Corp now owns 65,525 shares of the company’s stock worth $513,000 after buying an additional 20,700 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Dimension Therapeutics by 0.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 29,152 shares of the company’s stock worth $228,000 after buying an additional 89 shares in the last quarter. Finally, Teachers Advisors Inc. raised its position in shares of Dimension Therapeutics by 224.3% in the second quarter. Teachers Advisors Inc. now owns 19,204 shares of the company’s stock worth $115,000 after buying an additional 13,283 shares in the last quarter. 85.80% of the stock is currently owned by hedge funds and other institutional investors.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.